How Becton Dickinson Can Transform Medical Device Manufacturing and Patient Safety with Agentic AI
How Becton Dickinson Can Transform Medical Device Manufacturing and Patient Safety with Agentic AI
Agentic AI in medical device manufacturing is quickly moving from an interesting concept to a practical lever for quality, throughput, and patient safety. For a global manufacturer like Becton Dickinson (BD), the opportunity is not “more AI dashboards.” It’s building agentic workflows that can pull evidence across systems, draft compliant outputs, execute the right next steps, and escalate decisions to humans with the right guardrails.
That matters because medtech manufacturing is one of the rare environments where speed and caution must coexist. Deviation cycle times, CAPA backlogs, and complaint handling delays don’t just hit cost and delivery. They can increase patient risk when signals are missed, containment is slow, or traceability is incomplete.
This guide lays out what agentic AI in medical device manufacturing actually is, where it can drive the biggest gains for BD, and how to make it audit-ready from day one.
Why “Agentic AI” Matters Now for BD and the Industry
Medical device manufacturing is under pressure from multiple angles at once: rising complexity, multi-site variability, supplier volatility, workforce constraints, and sustained regulatory scrutiny. At the same time, teams are expected to improve medical device manufacturing quality without slowing output.
Traditional automation and analytics help, but they often plateau:
Dashboards describe what happened, but they don’t move work forward.
RPA can execute clicks, but it breaks when processes change or inputs aren’t clean.
Point AI models can predict outcomes, but they rarely orchestrate cross-system actions.
Agentic AI changes the equation by introducing software agents that can plan, execute, verify, and escalate work within defined constraints. Instead of sending people on a scavenger hunt across eQMS, MES, ERP, LIMS, and document control, an agent can assemble the evidence pack, draft the investigation narrative, open the right workflows, and route it for approval.
When done well, agentic AI in medical device manufacturing connects directly to patient safety outcomes:
Fewer escapes through faster detection and containment
More consistent investigations with evidence-linked reasoning
Earlier post-market surveillance signals through structured intake and clustering
Stronger recall readiness through better traceability across the digital thread
Definition: What is agentic AI in medical device manufacturing?
Agentic AI in medical device manufacturing is a system of AI agents that can interpret regulated context (procedures, specifications, batch history, complaint data), orchestrate multi-step workflows across enterprise tools, and produce audit-ready outputs while keeping high-risk decisions under human control.
What Agentic AI Is (and What It Isn’t) in a Regulated Environment
If you work in Quality, Regulatory, Validation, or Manufacturing Engineering, the hype around autonomy can be a non-starter. The practical framing is simpler: agentic AI is a workflow engine with reasoning capabilities, not a replacement for the QMS.
Agentic AI vs. traditional AI/ML vs. RPA
Each approach has a role, but they solve different problems:
Traditional AI/ML: Great for prediction and classification (for example, predicting drift or classifying complaint narratives), but it usually stops at “insight.”
RPA: Great for deterministic, stable processes (copying fields, moving files), but fragile when inputs vary or workflows evolve.
Agentic AI: Great for orchestrating messy, cross-system processes by combining retrieval, reasoning, and tool use, with verification steps and escalation paths.
A useful mental model is that agentic AI coordinates work the way a strong junior engineer or quality specialist would: gather evidence, follow the SOP, propose the next steps, and ask for approval when the decision crosses a risk threshold.
The guardrails BD would need
In regulated manufacturing, agentic AI for quality management only works if the system is designed for control, not surprise. Guardrails typically include:
Human-in-the-loop approvals for decisions that impact product disposition, validated state, or regulatory reporting
Role-based permissions so agents can only access and act within the user’s scope
Versioning and change control for prompts, tools, workflows, and knowledge sources
Full audit trails for every action: inputs, context retrieved, outputs generated, approvals, timestamps
Data boundaries and privacy controls for PHI/PII that may appear in complaints and service records
This is also where platform selection matters. BD would need an orchestration layer that can connect across systems, enforce access control, and lock production workflows to prevent accidental changes. In practice, that’s the difference between a pilot and a program.
Validation and compliance realities (high-level)
Agentic AI in medical device manufacturing has to fit inside a risk-based assurance mindset. That means defining:
Intended use and boundaries (what the agent can do, what it must never do)
Failure modes (hallucinated root cause, missed evidence, wrong routing, over-confident language)
Verification steps (checklists, evidence requirements, confidence thresholds)
Monitoring and change management (drift, workflow updates, retraining, controlled releases)
The goal is not to “prove the model is perfect.” It’s to prove the system is safe, controlled, and consistently produces outputs that humans can review and rely on.
Highest-Impact Use Cases for BD: From Factory Floor to Post-Market
The best use cases for agentic AI in medical device manufacturing share three traits: high volume, high friction, and clear evidence requirements. Below are the strongest starting points for BD, mapped to quality and safety outcomes.
Top agentic AI use cases for medical device manufacturing
Deviation triage and investigation drafting
AI-driven CAPA automation and monitoring
Supplier quality intelligence and incoming inspection support
Process monitoring and predictive maintenance with validated-state guardrails
Digital batch record review and evidence pack generation
Complaint handling acceleration and structured intake
Post-market surveillance signal detection and escalation playbooks
Deviation triage and investigation (NCR/MRB)
Deviations are where time disappears: collecting batch history, reviewing equipment logs, correlating environmental monitoring, checking training records, and hunting down attachments.
An agentic workflow can:
Pull relevant batch genealogy, process parameters, alarms, and operator actions from MES/eBR
Retrieve the applicable SOPs, work instructions, and specs from document control
Check training and certification status for involved roles
Summarize the event timeline and flag missing evidence
Draft an investigation narrative with linked evidence for QA review
Recommend containment steps (for example, hold, segregate, additional sampling) under predefined rules
Route to MRB or specialist review when thresholds are met
This is deviation investigation automation that doesn’t skip rigor. It simply removes the scavenger hunt.
CAPA acceleration without cutting corners
AI-driven CAPA automation is one of the highest ROI opportunities because CAPAs accumulate silently. The backlog grows, effectiveness checks slip, and recurring issues persist.
An agent can:
Cluster related deviations, nonconformances, and complaints by failure mode, line, supplier, or component
Suggest CAPA candidates based on recurrence and risk signals
Draft CAPA plans using approved templates and controlled language
Propose effectiveness checks aligned to the failure mechanism
Monitor due dates, dependencies, and overdue actions
Escalate bottlenecks to owners and management automatically
This is where agentic AI for quality management can improve consistency across sites by standardizing how CAPAs are drafted and tracked, while keeping approval authority with Quality.
Supplier quality and incoming inspection intelligence
Supplier variability is a major driver of escapes and line disruption. But supplier quality data is often fragmented: SCARs in one system, COAs in another, inspection results in spreadsheets, and risk decisions living in tribal knowledge.
An agentic workflow can:
Monitor SCAR trends, incoming acceptance rates, and lot disposition outcomes
Cross-reference supplier changes, material revisions, and complaint correlations
Recommend risk-based sampling adjustments based on recent performance
Trigger early warnings when drift is detected (before a major event)
Generate supplier performance summaries for review meetings
Done carefully, this supports ISO 13485 AI compliance expectations around controlled processes and documented rationale, because the agent can package the evidence and reasoning for a human decision.
Process monitoring and predictive maintenance (with safety in mind)
Predictive maintenance is not new. What’s new is using an agent to connect signals to action, while preserving the validated state.
An agent can:
Detect process drift using trends and alarms
Identify likely causes (tool wear, calibration issues, environmental excursions)
Recommend maintenance work orders, inspections, or checks
Escalate any parameter change or process adjustment to engineering and quality approval
Record the rationale and evidence for the action taken
In regulated environments, the core rule is simple: agents can recommend broadly, but they should only execute changes that are explicitly low-risk and pre-approved.
Digital batch record review (speed and accuracy)
Batch record review is a classic pain point: repetitive checks, missing signatures, mismatched timestamps, attachment verification, and exceptions that require back-and-forth.
Agentic AI in medical device manufacturing can:
Validate completeness (required fields, attachments, sign-offs)
Detect inconsistencies (out-of-sequence steps, missing calibration references)
Flag anomalies for human review
Generate a structured batch release evidence pack
Draft the release summary for QA to approve
This can reduce release cycle time while improving consistency, especially across multiple plants.
Complaint handling and post-market surveillance signal detection
Complaints often arrive as messy narratives, call logs, emails, or service notes. The work is labor-intensive: deduplicate, extract failure mode, map to product/UDI, and decide what to escalate.
An agent can:
Normalize complaint intake into structured fields
Detect duplicates and link related cases
Extract failure modes and map to known issues
Associate complaints to lots and UDI traceability AI linkages
Trigger escalation playbooks when thresholds are hit (severity, recurrence, geography, time window)
Support AI for post-market surveillance by clustering signals early, without waiting for quarterly reviews
This is one of the most direct pathways from operational efficiency to patient safety impact.
Patient Safety Outcomes: How Agentic AI Reduces Risk in Practice
It’s easy to say “better quality equals better safety.” The more useful view is to map agentic AI in medical device manufacturing to the actual risk mechanics.
Risk management mapping (ISO 14971 lens)
Risk management ISO 14971 AI discussions become practical when you focus on where harm chains can be broken:
Hazard → sequence of events → hazardous situation → harm
Agentic AI can interrupt that chain by improving:
Detection: spotting deviations, drift, and complaint clusters earlier
Containment: triggering holds, segregation, and additional checks faster
Corrective action: accelerating investigation and CAPA execution
Preventive action: identifying recurrence patterns across sites and suppliers
Communication: packaging evidence and routing the right stakeholders quickly
Faster time-to-containment and fewer escapes
The measurable safety-related operational metrics BD could improve include:
Time from deviation creation to containment action
Repeat deviation rate for the same failure mode
Complaint cycle time (intake to triage, triage to decision)
Escape rate (internal defects that become external complaints)
CAPA cycle time and on-time completion
Audit readiness indicators (completeness, traceability, documentation consistency)
Even when outcomes like recalls are rare, leading indicators like escape rate and containment time are practical proxies for risk reduction.
Traceability and recall readiness (UDI and digital thread)
In a high-pressure field event, speed comes from traceability. Agentic AI can help connect:
Complaint → device identifier/UDI → lot/batch → materials/suppliers → equipment and parameters → operators and training → distribution and customers
That end-to-end mapping is the manufacturing digital thread in action, and it’s where agentic workflows can dramatically reduce the time needed to answer the hardest questions during an investigation.
Data and Systems BD Needs to Make Agentic AI Real (Architecture Blueprint)
Agentic AI in medical device manufacturing isn’t a single system. It’s an orchestration layer that ties together the tools BD already runs.
The core systems an agent must orchestrate
Most high-value workflows cross multiple sources:
eQMS: deviations, CAPA, change control, audits
MES/eBR/DHR: batch execution, genealogy, alarms, step-level records
ERP: inventory, suppliers, purchasing, disposition actions
PLM: design history, BOM, revisions, specifications
LIMS: lab results, stability, environmental monitoring
Complaint handling/CRM: intake, service events, field feedback
Training/LMS: qualifications, currency, role requirements
CMMS/calibration: maintenance history, calibration status
Document control: SOPs, work instructions, forms, templates
To work reliably, the agent needs both read access (retrieve evidence) and controlled write access (create tickets, draft records, route workflows), with permissions based on role and risk.
Data readiness checklist
Before building agents, BD teams should align on a few fundamentals:
Master data consistency: parts, suppliers, sites, equipment, UDIs, lots
Controlled taxonomies: deviation types, failure modes, complaint codes
Document metadata quality: owners, effective dates, revision history
Linkages: lot to supplier lot, complaint to device/lot, equipment to batch steps
Data lineage: where key fields come from and what is considered authoritative
Quality thresholds: what “good enough” data looks like for each workflow
This is not a prerequisite for perfection. It’s a prerequisite for predictable outcomes.
Model strategy: retrieval plus tools, not magic
In regulated settings, the most reliable pattern is:
Retrieval-augmented generation over controlled documents and records
Tool use to take actions in systems (create workflows, pull batch history, assign tasks)
A policy layer that defines what the agent may do, must ask approval to do, and must never do
This is also how you reduce hallucinations: the agent should ground outputs in retrieved evidence, and the workflow should enforce verification before anything high-impact happens.
Governance, Security, and Compliance: Making It Audit-Ready
Most medtech leaders don’t reject AI because it’s inaccurate. They reject it because it’s hard to defend. The bar is audit readiness.
Audit trails and explainability
For agentic AI in medical device manufacturing, “explainability” should mean operational traceability:
What inputs were used?
What records and documents were retrieved?
What output was generated?
What actions were taken, by whom, and when?
What approvals occurred?
What version of the workflow, tools, and knowledge sources were active?
A strong approach is automatic evidence packaging: the agent produces the draft plus the supporting artifacts, so reviewers can validate quickly.
Validation approach (risk-based)
A practical risk-based approach includes:
Define intended use and prohibited uses
Classify task risk (drafting vs executing vs disposition decisions)
Create test sets from real historical cases (deviations, CAPAs, complaints)
Evaluate output quality: completeness, correctness, adherence to templates, tone and compliance language
Monitor drift: model updates, data changes, taxonomy changes
Enforce change control: versioning, approval to promote changes to production
This supports FDA QMSR readiness because it brings discipline to software behavior in the quality system.
Cybersecurity and privacy considerations
Complaint handling often includes PHI/PII. That creates additional requirements:
Least privilege access and network segmentation
Strong authentication (SSO) and role-based access control
Data retention controls and the ability to limit logging for sensitive workflows
Vendor and third-party model risk management
Clear policies for where data is processed and stored
For many organizations, on-premise or controlled deployment options are important for sovereignty and regulated environments.
Ethics and safety-by-design
Even in manufacturing, over-automation is a safety risk. Best practice guardrails include:
“Stop-the-line” escalation triggers for critical signals
Conservative defaults when confidence is low
Human review for anything that affects product disposition, labeling, or regulatory reporting
Controlled language and templates to avoid misleading certainty
A Practical 90-Day Pilot Plan for BD (and How to Scale)
A credible pilot for agentic AI in medical device manufacturing should be narrow, measurable, and built to scale.
Pick the right pilot use case
The best first use cases are:
High volume and repetitive
Clear inputs and outputs
Low-to-moderate risk if scoped correctly
Easy to measure cycle time and quality improvements
A strong example: deviation triage plus investigation drafting in one plant, where the agent assembles evidence and drafts the initial investigation, but QA approves all conclusions and actions.
Success metrics (operational and safety)
Define success with a mix of speed, quality, and adoption:
Reduction in deviation cycle time (creation to investigation draft)
Reduction in CAPA backlog growth rate
Batch review time reduction
Complaint triage time reduction
Decrease in rework loops (fewer missing attachments, fewer incomplete narratives)
Audit readiness indicators (completeness, traceability, consistency)
User trust and adoption (how often drafts are accepted with minor edits)
Change management and training
The pilot succeeds when Quality and Operations own it together. Practical steps include:
Involve QA/RA and validation early in workflow design
Update SOPs to reflect how drafts are generated and reviewed
Define escalation rules and approval roles clearly
Train reviewers on how to validate evidence packs quickly
Scaling across sites
Scaling agentic AI for quality management across BD sites requires standardization without forcing uniformity where it doesn’t fit.
A workable model:
Standardize taxonomies, templates, and evidence requirements centrally
Allow site-specific parameters (systems, equipment, workflows) via configuration
Maintain central governance for versions, approvals, and monitoring
Use an iterative rollout: prove one workflow in one site, then replicate with controlled variation
Common Pitfalls (and How BD Can Avoid Them)
Many agentic initiatives fail for predictable reasons. Avoiding these early is often the difference between a stalled pilot and a multi-site deployment.
Treating agentic AI as a chatbot instead of workflow orchestration A chat interface alone doesn’t reduce cycle time. The value comes from connecting systems, executing steps, and producing structured outputs.
Building on an uncontrolled knowledge base If procedures, templates, and specs are outdated or poorly indexed, the agent will behave inconsistently. Controlled sources and metadata matter.
Over-automating regulated decisions Agents should draft, recommend, and route. Humans should approve high-risk decisions until the organization has evidence that limited automation is safe.
No clear ownership across IT, Quality, and Operations Agentic AI in medical device manufacturing touches all three. A single accountable owner plus a cross-functional governance group prevents deadlocks.
Ignoring drift and change control for prompts and tools In regulated environments, “small changes” can have big downstream effects. Versioning and approval flows are essential.
Conclusion: The Competitive Advantage of Safety-Led AI
Agentic AI in medical device manufacturing is not about replacing quality systems. It’s about making them faster, more consistent, and more defensible by turning fragmented evidence into audit-ready outputs and guided actions.
For BD, the strongest path forward is staged adoption: augment experts first, automate low-risk steps second, and expand only when performance and controls are proven. That approach improves throughput and cost, but more importantly, it strengthens patient safety by reducing escapes, accelerating containment, and improving traceability across the digital thread.
If you’re evaluating where to begin, start with one high-volume workflow in deviations, CAPA, or complaints, define the guardrails, and prove measurable results in 90 days.
Book a StackAI demo: https://www.stack-ai.com/demo
